Clinical trials: Non Therapeutic Body Modification
Obesity, Overweight
Predicting Adherence to a Heart-Healthy Diet in Lean and Obese Individuals
Background: Sticking to a diet plan can be difficult, but is important for many different health reasons. Some people seem to have a harder time following and sticking to a diet plan than others.
- Trial name
- NCT01862796
- Testing
- Underfeeding diet, Weight maintaining diet
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Cachexia; Cancer, Cachexia
Master Protocol for the Study of Rilogrotug for the Treatment of Weight Loss and Anorexia in Patients With Cancer Cachexia and mCRC or mNSCLC
The purpose of this trial is to learn whether participants who take rilogrotug gain weight, have a better appetite, and have a better quality of life than participants who do not take rilogrotug (placebo arm).
- Conditions
- Cachexia; Cancer, Cachexia, Cachexia-Anorexia Syndrome, Metastatic Colorectal Cancer (CRC)
- Trial name
- REACH (NCT07888075)
- Testing
- Rilogrotug
- Volunteers
- 950 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Cachexia, Non-Small Cell Lung Cancer
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1)
The administration of Anamorelin in patients with Stage III-IV non-small cell lung cancer-cachexia (NSCLC-C) is expected to increase appetite, lean body mass, weight gain, and muscle strength.
- Trial name
- NCT01387269
- Testing
- Anamorelin HCl
- Where
- 60 sites in United States, Belarus and 14 more
- Volunteers
- 484 people
- Sponsor
- Helsinn Therapeutics (U.S.), Inc
Cachexia, Non-Small Cell Lung Cancer
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2)
The administration of Anamorelin in patients with Stage III-IV non-small cell lung cancer-cachexia (NSCLC-C) is expected to increase appetite, lean body mass, weight gain, and muscle strength.
- Trial name
- NCT01387282
- Testing
- Anamorelin HCl
- Where
- 46 sites in United States, Australia and 5 more
- Volunteers
- 495 people
- Sponsor
- Helsinn Therapeutics (U.S.), Inc
Stage IV Non-small Cell Lung Cancer, Cachexia
Ruxolitinib for Cancer Cachexia
To assess toxicity with use of Ruxolitinib in NSCLC cachexia patients; to associate levels of JAK/STAT signaling in blood, adipose, and muscle pre- and post-ruxolitinib treatment with changes in cachexia and anorexia.
- Trial name
- NCT04906746
- Testing
- Identify any dose-limiting toxicity (DLT) when ruxolitinib is administered to NSCLC cachexia patients.
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Tu Dan
Chronic Low-back Pain (cLBP), Non Specific Chronic Low Back Pain
TECAR Therapy in Chronic Back Pain
The goal of this clinical trial is to learn whether adding high-intensity electromyostimulation (Hi-EMS) to capacitive and resistive electric transfer (TECAR) therapy improves pain and functional performance in adults with…
- Trial name
- NCT07821021
- Testing
- TECAR Therapy plus Hi-EMS, Tecar therapy alone
- Volunteers
- 37 people
- Sponsor
- University of Hartford
Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)
Sarcopenia and Cachexia in Patients With Lung Cancer
The PHILICA study investigates whether muscle mass, muscle strength, and muscle function are associated with treatment tolerance, quality of life and survival in patients with lung cancer.
- Trial name
- PHILUCA (NCT06730685)
- Where
- Denmark
- Volunteers
- 160 people
- Sponsor
- Zealand University Hospital
Neoplasms Pancreatic
Immunostimulating Interstitial Laser Thermotherapy in Pancreatic Cancer
Thermotherapy is a technology aiming at destroying tissue, for example tumor tissue. Immunostimulating Interstitial Laser Thermotherapy (imILT) is a specific form of thermotherapy, which, in addition to destroying tumor tissue…
- Trial name
- NCT02973217
- Testing
- Immunostimulating Interstitial Laser Thermotherapy
- Where
- France
- Volunteers
- 5 people
- Sponsor
- Clinical Laserthermia Systems AB